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Abstract
Background: The expression of the chemokine receptor CCR6 has been previously correlated with higher grades
and stages of breast cancer and decreased relapse-free survival. Also, its cognate chemokine ligand CCL20 has been
reported to induce proliferation of cultured human breast epithelial cells.
Methods: To establish if CCR6 plays a functional role in mammary tumorigenesis, a bigenic MMTV-PyMT CCR6-null
mouse was generated and mammary tumor development was assessed. Levels of tumor-infiltrating immune cells
within tumor-bearing mammary glands from MMTV-PyMT Ccr6WT and Ccr6−/− mice were also analyzed.
Results: Deletion of CCR6 delayed tumor onset, significantly reduced the extent of initial hyperplastic outgrowth,
and decreased tumor incidence in PyMT transgenic mice. CCR6 was then shown to promote the recruitment of
pro-tumorigenic macrophages to the tumor site, facilitating the onset of neoplasia.
Conclusions: This study delineated for the first time a role for CCR6 in the development of breast cancer, and
demonstrated a critical function for this receptor in maintaining the pro-tumorigenic cancer microenvironment.
Keywords: Breast Cancer, Mammary Gland, Chemokine Receptor, CCR6, Transgenic Mouse Model, Immune System,
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Introduction
Breast cancer is one of the leading causes of cancer-
related death in women world-wide. Evasion of the
immune system is a hallmark of cancer, and aids tumor
cells to survive, intravasate, and potentially form distal
metastases [1]. As such, the tumor microenvironment
has a profound effect on the development and progres-
sion of malignancies, and it has been suggested that
levels of infiltrating immune cells correlate with stage
and aggressiveness of human breast cancer [2]. In particu-
lar, tumor-associated macrophages (TAMs) have been
found to play an important part in facilitating breast
tumor development [3] through polarization from a
classically-activated “M1” anti-tumor resident cell within
adult mammary tissue to an alternatively-activated “M2”
pro-tumor phenotype [4]. This “switch” results in shifts in
cell metabolism, a decrease in pro-inflammatory chemo-
kine/cytokine production, poor antigen-presentation abil-
ity, and suppression of T cell responses. In addition, M2
TAMs promote angiogenesis, cell proliferation and tissue
remodeling (reviewed in [5]).
Chemokines and their cognate receptors are involved
in the development, migration and activation of many
different types of immune cells, both adaptive and
innate. Small molecular-weight proteins, chemokines
bind to their cognate seven-transmembrane domain
G-protein coupled receptors (GPCRs), activating a
multitude of signaling pathways, which mediate many
different homeostatic and inflammatory functions. Im-
portantly, a large body of literature in the last decade
has linked the action of chemokines and chemokine
receptors to cancer progression and metastasis [6].
* Correspondence: marina.kochetkova@adelaide.edu.au
1Department of Molecular and Cellular Biology, School of Biological Sciences,
University of Adelaide, Adelaide, South Australia, Australia
Full list of author information is available at the end of the article
© 2015 Boyle et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Boyle et al. Molecular Cancer  (2015) 14:115 
DOI 10.1186/s12943-015-0394-1
The CC-chemokine receptor CCR6 is expressed on
dendritic cells [7, 8], regulatory T cells and various T
helper lymphocyte subsets [9, 10], and mediates their
migration and function via stimulation with its ligand
CCL20 (also known as macrophage inflammatory pro-
tein (MIP)-3α [11]). CCR6 is also expressed on natural
killer cells, B lymphocytes, neutrophils [12] and macro-
phages [10, 13]. Despite the significant role of TAMs in
breast cancer, the expression and function of CCR6
within the macrophage population has not been shown
within the mammary gland.
Interestingly, together with CCL20, CCR6 expression
has been correlated with stage and prognosis in a variety
of cancers including hepatocellular carcinoma [14, 15],
colorectal carcinoma [16–18], glioma [19], and non-
small cell lung cancer [20], and a function for CCR6 in
regulation of cancer progression has been putatively
demonstrated using cell lines and xenograft models [16,
18, 21, 22]. In breast cancer, higher CCR6 expression
levels were linked with tumor stage and grade [23], and
incidence of metastasis to the pleura [24]. Stimulation of
ex vivo mammary peritumoral cells with CCL20 was
found to increase their proliferation rate, invasiveness
and migration [25]. CCL20 is also upregulated in human
triple negative breast cancer cell lines [26]. Moreover, it
was recently proposed that the presence of CCR6 may
act as a prognostic factor for breast cancer patient
survival [23]. However, no causative or functional link
between the CCR6-CCL20 axis and progression of
breast cancer has been documented to date.
In this study we have utilized a well-characterized
transgenic model for breast cancer, in which the poly-
oma middle-T oncogene is activated under control of
the mouse mammary tumor virus promoter (MMTV-
PyMT) [27]. This transgenic model has been shown to
closely mimic the stages of human breast disease from
initial hyperplasia, through to ductal carcinoma in situ
and invasive ductal carcinoma [28]. Crossing this trans-
genic mouse with a CCR6-null mouse to generate a
bigenic MMTV-PyMT Ccr6−/− animal model has allowed
us to directly assess the role of CCR6 in mammary
tumorigenesis in vivo. The results demonstrated that
CCR6 promotes breast cancer initiation and progression
through maintenance of pro-tumorigenic TAMs within
tumor-bearing mammary glands, warranting further
investigation of CCR6 as a possible therapeutic target.
Results
CCR6 expression increases throughout cancer
development and results in a higher number of
mammary tumors
To first determine whether CCR6 may play a role in the
regulation of mammary neoplasia, we investigated ex-
pression of the receptor in CD45-negative normal mouse
mammary cells, and cells from various tumor stages
(representative H&E pictures in Fig. 1a). CCR6 was
expressed on a low proportion of normal mammary
cells, but this proportion was greatly amplified in
accordance with increasingly higher grades of MMTV-
PyMT cancer including initial hyperplasia, early carcin-
oma and late carcinoma as indicated (Fig. 1a). This is
consistent with human breast cancer [23] and other
mouse models of cancer [17]. Additionally, in both non-
PyMT Ccr6WT and MMTV-PyMT Ccr6WT mammary
tissues the ligand for CCR6, CCL20, was highly expressed
at concentrations over 50 ng/mg tissue (Fig. 1b). These
data raise the possibility of a role for CCR6 in breast can-
cer development.
To next establish the role of CCR6 deletion on mam-
mary tumorigenesis, we compared the rate and total
extent of PyMT-driven neoplasia between MMTV-
PyMT Ccr6WT and Ccr6−/− mice. Tumor onset was
significantly delayed in MMTV-PyMT Ccr6−/− mice
(Fig. 1c), with some mice not developing palpable
tumors until 150 days old (21 weeks) compared to a
maximum onset age of 130 days old (18 weeks) for
MMTV-PyMT Ccr6WT counterparts (Fig. 1d).
In order to assess the impact of CCR6 on the later
stages of cancerogenesis, MMTV-PyMT Ccr6WTand
Ccr6−/− mice were sacrificed at 22–24 weeks of age and
the total number of mammary tumors per mouse was
determined. We found that MMTV-PyMT Ccr6−/− mice
had significantly decreased tumor incidence compared
to MMTV-PyMT Ccr6WT animals (Fig. 1e). Together,
these results implicate CCR6 as being an important
player in breast oncogenesis.
CCR6 deletion significantly delays tumor initiation in vivo
We then sought to examine whether CCR6 influenced
early hyperplasia of mammary glands during tumor
initiation as well as late stage tumorigenesis. Glands
from 8-week-old MMTV-PyMT Ccr6−/− and Ccr6WT
mice were extracted and whole mounted for quantita-
tion of hyperplastic/early-neoplastic lesions (represen-
tative images from both genotypes shown in Fig. 2a).
We found that the deletion of CCR6 significantly
reduced the initial hyperplastic outgrowth within the
gland (Fig. 2b), a common indicator of future breast
cancer development. As the total area of PyMT-
driven hyperplastic outgrowth per gland was reduced
by threefold in CCR6-null animals, we concluded that
the effect of CCR6 on mammary tumorigenesis is
manifested very early on in cancer development.
The difference seen in early tumor initiation between
MMTV-PyMT Ccr6WT and Ccr6−/− mice can potentially
result from a difference in normal mammary develop-
ment, which may then have translated into decreased
hyperplasia. We therefore extracted pubertal mammary
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glands from non-PyMT 6-week-old Ccr6WT and Ccr6−/−
mice. Representative glands are shown in Additional
file 1: Figure S1a. When ductal epithelial growth was
quantitated, we observed no statistically significant
difference in ductal length, number of terminal end
structures or branching between Ccr6WT and Ccr6−/−
mice (Additional file 1: Figure S1b-d), and hence the
overall effect of CCR6 deletion on normal mammary
Fig. 1 CCR6 expression increases throughout cancer development and results in a higher number of mammary tumors. a Top: Representative
H&E images of mammary tissue from normal gland and various stages of PyMT-driven tumorigenesis as indicated. Scale bar is 200 μm. Bottom:
Proportion of CCR6-positive epithelial cells (CD45-negative) purified from mammary glands at respective stages of tumorigenesis. 18 normal
samples (2 glands/sample), 7 hyperplastic samples (2 glands/sample), 6 early carcinomas and 3 late carcinomas were analyzed. b ELISA for CCL20,
the ligand for CCR6, in normal (left) and early neoplastic MMTV-PyMT Ccr6WT (right) mammary glands. n = 4 samples per genotype. c Kaplan-Meier
analysis of the palpable tumor onset in MMTV-PyMT Ccr6−/− mice (n = 14) vs MMTV-PyMT Ccr6WT mice (n = 11). d Age of tumor onset in
MMTV-PyMT Ccr6−/− mice and MMTV-PyMT Ccr6WT mice. e Mammary tumor incidence in MMTV-PyMT Ccr6WT (n = 9) and
Ccr6−/− (n = 14) mice
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gland biology appears to be minimal and is unlikely
to account for differences in PyMT-driven tumor
development between the two genotypes. Further-
more, the levels of CCL20 were not statistically differ-
ent between non-PyMT Ccr6WT and MMTV-PyMT
Ccr6WT mammary tissues (Fig. 1b), demonstrating
that the expression of CCL20 is not affected by the
process of tumorigenesis. Taken together, these data
show that early stage tumorigenesis is mediated by a
CCR6-dependent mechanism, without affecting nor-
mal mammary morphogenesis.
CCR6 promotes mammary gland neoplasia independently
of cancer epithelial cells or stem-like cells
To investigate the mechanism underlying CCR6-driven
mammary tumorigenesis, we studied the epithelial cell
population to determine if CCR6 was having a direct
effect on cell proliferation. Cells at the stage of early
neoplasia from MMTV-PyMT Ccr6WT mammary glands
were assayed for proliferation upon stimulation with
CCL20. No differences in cell proliferation were observed
(Fig. 3a). Furthermore, Ki67 staining of sectioned hyper-
plastic mammary glands from MMTV-PyMT Ccr6WT and
Ccr6−/− mice showed that epithelial cells in knock-out
mice are still able to adequately proliferate and staining of
Ki67 is equal to that in the Ccr6WT (Fig. 3b). This suggests
that the role of CCR6 in breast cancer is independent of
epithelial cells.
We next determined whether CCR6 may exert its
effect by skewing distinct cell populations within the
bulk epithelium, as we have reported previously for the
chemokine receptor CCR7 [29]. The current prevailing
paradigm has mammary epithelial and breast cancer
cells hierarchically organized with a self-renewing, quies-
cent, multipotent progenitor (or stem-like cell) popula-
tion giving rise to basal and luminal progenitors which
in turn differentiate into specific lineages making up the
mammary gland and heterogenous breast tumors [30].
Recently, a number of immune mediators including
chemokine receptors have been implicated in mainten-
ance of the cancer stem-like cells within mammary
tumors (reviewed in [31]). We therefore tested the
Fig. 2 CCR6 deletion significantly delays tumor initiation in vivo. a Representative whole mount images of MMTV-PyMT Ccr6WT (n = 6) and Ccr6−/−
(n = 6) mice at 8 weeks of age. LN = lymph node. Black arrowheads indicate hyperplastic lesions within the glands. b Quantitation of area
of pre-neoplastic lesions in 8 week-old MMTV-PyMT mice
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Fig. 3 CCR6 promotes mammary gland neoplasia independently of cancer epithelial cells. a Proliferation assay of mammary epithelial cells
purified from MMTV-PyMT Ccr6WT mice at the stage of early neoplasia with and without stimulation by recombinant CCL20 (100 ng/ml).
Fetal calf serum (0.5 %) and EGF (20 ng/ml) were used as positive controls. Data are representative of 3 independent experiments, n = 3
mice per experiment. b Analysis of Ki67-positive proliferating cells within MMTV-PyMT Ccr6WT and Ccr6−/− mice at the stage of early
neoplasia. Shown are representative fields from 2 separate tumors per genotype, displaying equal distribution of cells positive for Ki67
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potential link between the tumor-promoting function of
CCR6 and breast cancer stem-like cell pools.
Freshly isolated MMTV-PyMT Ccr6WT and Ccr6−/−
mammary cells from pre-neoplastic mice at 8–9 weeks-
old were assayed by flow cytometry for expression of cell
surface markers CD24 and CD29 [32] (representative
plots shown in Fig. 4a), which were previously used to
define stem cells in the MMTV-PyMT [33, 34] and
other breast cancer mouse models [35, 36]. We found
that the deletion of CCR6 did not alter the proportions
Fig. 4 CCR6 promotes mammary gland neoplasia independently of cancer stem-like cells a-b Single cell suspensions (CD45-negative) from
mammary glands with early neoplasia from MMTV-PyMT Ccr6WT and Ccr6−/− mice were analyzed by flow cytometry for the expression of
CD24 and CD29 to quantitate the proportions of basal and luminal cell lineages. c Mammosphere-forming efficiency of cells isolated from
MMTV-PyMT Ccr6WT and Ccr6−/− mammary glands. a-c Data are representative of 3 independent experiments, n = 6 mice per genotype
per experiment. d Mammosphere-forming efficiency of MMTV-PyMT Ccr6WT cells stimulated with varying concentrations of CCL20. Data
are representative of 3 independent experiments, n = 3 individual mice per experiment. e Representative whole mount images and quantitation of
the neoplastic outgrowth area in Ccr6WT recipients of MMTV-PyMT Ccr6WT and MMTV-PyMT Ccr6−/− mammary tumor tissue transplants; n = 4 recipient
mice per group, LN = lymph node. Black arrowheads indicate donor transplant outgrowth within the glands
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of the stem cell-enriched basal population (CD24+CD29hi)
nor the luminal population (CD24+CD29lo) (Fig. 4b) in
hyperplastic mammary glands.
We also investigated the effect of CCR6 ablation on
functional stem-like mammary cancer cell pools using
the mammosphere assay, which is used to select for
colonies of early stem-like progenitors [37]. Pre-
neoplastic MMTV-PyMT Ccr6WT and Ccr6−/− mammary
cells were seeded into non-adherent mammosphere
culture and allowed to grow for 7 days. The deletion of
CCR6 did not alter mammosphere-forming efficiency
(Fig. 4c), and when sphere cultures were stimulated with
varying concentrations of CCL20, no change in their
ability to form mammospheres (Fig. 4d) was observed,
supporting results obtained using flow cytometric analysis.
Having found no difference in the proportion or func-
tion of stem cell-like pools within early tumorigenic
lesions, we next tested a bona fide property of cancer
stem cells – their ability to propagate tumors upon
transplantation. MMTV-PyMT Ccr6WT and Ccr6−/−
donor mammary tissue was transferred into recipient fat
pads of syngeneic non-PyMT Ccr6WT mice. Using this
approach, we found no significant difference between
MMTV-PyMT Ccr6WT and Ccr6−/− tissue in the ability
to form outgrowths when transplanted into Ccr6WT
recipients (Fig. 4e), indicating that the deletion of CCR6
did not reduce the tumor-propagating capability of
mammary epithelium.
Altogether, these results demonstrate that the role of
CCR6 in breast cancer is independent of breast epithelial
and progenitor cells, raising the possibility that its mech-
anism of action involves the tumor microenvironment.
CCR6 mediates the recruitment of pro-tumorigenic
macrophages to the mammary tumor microenvironment
To test whether the reduced mammary tumorigenesis
caused by the deletion of CCR6 was due to an effect of
the CCR6-CCL20 axis on the tumor microenvironment
we next investigated by flow cytometry the levels and
identity of tumor-infiltrating leukocytes in mammary
tumors at the stage of early carcinoma (see Fig. 1a).
Tumor-associated macrophages have been extensively
implicated in tumor promotion both in the mammary
gland and elsewhere, due to their role in angiogenesis,
cell proliferation and tissue remodeling [5]. To initially
examine the polarization of TAMs in the MMTV-PyMT
mice, macrophages were assessed for expression of
prototypic markers interleukin-4-receptor (IL4-R) and
mannose receptor (CD206), which have been used
previously in flow cytometric analysis to distinguish
alternatively-activated M2 macrophages from classically-
activated M1 [38–42]. We estimated using these markers
that a high proportion of TAMs were of an M2-like
phenotype (Additional file 1: Figure S2a), as has been
suggested previously for MMTV-PyMT mammary tumors
[43]. Interestingly, CCR6 was found to be highly expressed
within the TAM population as it was detected on greater
than 60 % of total macrophages (Additional file 1: Figure
S2b). Most importantly, CCR6 was expressed at higher
levels and on a significantly higher proportion of putative
M2 macrophages (up to 90 %) than M1 (Fig. 5a and
Additional file 1: Figure S2b), using both IL4-R and
CD206 to delineate the populations. This strong correl-
ation potentially implicates CCR6 in the regulation of
pro-tumorigenic macrophages within the mammary
gland microenvironment.
We then assessed the levels of macrophages in mam-
mary tumors from MMTV-PyMT Ccr6WT and Ccr6−/−
mice, and found that the proportion and overall num-
bers of TAMs were significantly reduced in MMTV-
PyMT Ccr6−/− mammary tumors relative to Ccr6WT
(Fig. 5b). Furthermore, the deletion of CCR6 resulted in
a shift towards an M1 macrophage phenotype, defined
by both IL4-R and CD206 prototypic markers (Fig. 5c).
The deletion of CCR6 also resulted in reduced traffick-
ing of dendritic cells to the tumor site, consistent with
previous studies, which demonstrated a reduced overall
migratory ability of dendritic cells in CCR6-null mice
[44, 45]. Although, overall numbers of tumor-infiltrating
dendritic cells were much lower than the corresponding
macrophage population. Notably, the majority of tumor-
infiltrating dendritic cells were CCR6-positive, consistent
with previous findings [12] (Additional file 1: Figure S3).
We have also assessed CCR6 expression on B cells and
specific T cell subsets (helper T cells (Th), cytotoxic T
cells (Tc), and regulatory T cells (Treg)) within mam-
mary tumors. In agreement with earlier reports for vari-
ous biological settings [12, 46], all tested infiltrating
leukocyte subsets expressed CCR6 at varying levels.
When CCR6 was ablated, only the Tc cell subset showed
a slight increase in the MMTV-PyMT Ccr6−/− as a
proportion of CD45+ tumor-infiltrating cells, however
no significant differences were found in total cell num-
bers between the two genotypes (Additional file 1:
Figures S4 and S5).
Our findings thus suggest that CCR6 promotes mam-
mary tumorigenesis through an epithelium-independent
mechanism involving tumor-infiltrating macrophages.
CCR6-mediated pro-tumorigenic macrophages promote
breast cancer in vivo
We then sought to provide definitive evidence for the
macrophage-mediating function of CCR6 in mammary
tumor promotion using an in vivo macrophage reconsti-
tution assay. Reconstitution assays, sometimes referred to
as “add-back” assays, are frequently used to underscore a
role for various cellular subsets in multiple pathological
settings, and macrophage reconstitution has been used
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previously in mammary gland studies [47]. A schematic of
the experimental setup is shown in Fig. 6a. MMTV-PyMT
mammary tumor cells from Ccr6WT donor mice were
purified and transplanted into the inguinal mammary fat
pads of non-PyMT Ccr6WT and Ccr6−/− recipients at
5 weeks of age. Two days post-transplantation, TAMs
(CD45+F4/80+) were sorted from excised and dissociated
MMTV-PyMT Ccr6WT tumors (Fig. 6b) and orthotopi-
cally injected into a group of Ccr6−/− recipients as speci-
fied in Fig. 6a. All other recipients received sham
Fig. 5 CCR6 mediates the recruitment of pro-tumorigenic macrophages to the mammary tumor microenvironment. a Comparison of proportions
of CCR6-positive cells and levels of CCR6 within putative M1 and M2 macrophage populations, based on IL4-R (left) and CD206 (right) expression.
MFI = mean fluorescence intensity. Representative results from 3 independent experiments. b Proportion of TAMs in mammary tumors from
MMTV-PyMT Ccr6WT and Ccr6−/− mice as determined by flow cytometry. Data are representative of 3 independent experiments, n = 5-7 mice per
genotype per experiment. c Proportions of putative M1 and M2 macrophage subtypes within the TAM population in mammary tumors
from MMTV-PyMT Ccr6−/− mice relative to Ccr6WT, as determined by flow cytometry. Dotted line = FMO control. Data are representative of
4 independent experiments, n = 3 mice per genotype per experiment
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injections with vehicle only, followed by assessment of
mammary tumor growth 6 weeks later.
In agreement with the results from spontaneous tumori-
genesis studies, we have found that tumors grew signifi-
cantly slower in the Ccr6−/− hosts compared to Ccr6WT,
indicating that CCR6 is required in the mammary stroma
for robust tumor development. However, when the re-
duced macrophage phenotype was restored in Ccr6−/−
mice through orthotopical injections, the tumor latency
was significantly shortened, approaching that of the
Ccr6WT mice (Fig. 6c).
It was further found that the supplementation of Ccr6−/−
mice with TAMs restored the efficiency of tumor growth
(measured by weight of tumor-bearing mammary glands)
within these mice to that seen in the Ccr6WT, whilst
Ccr6−/− mice that received sham injections displayed
reduced tumorigenesis (Fig. 6d) as seen in the spon-
taneous model (see Fig. 1).
Enumeration of macrophages within grafted tumors
in Ccr6WT and Ccr6−/− mice (Fig. 6e) paralleled the
results seen in spontaneous mammary tumors (see
Fig. 5b). Whilst there was an upward trend towards
increased TAMs in the Ccr6−/− mice that received
TAM injections, the difference was not statistically signifi-
cant (Fig. 6e). This, combined with the decreased tumor
growth in the CCR6-null mice, indicated that the support
Fig. 6 CCR6-mediated pro-tumorigenic macrophages promote breast cancer in vivo. a Schematic of macrophage reconstitution assay to
determine contribution of macrophages to mammary tumorigenesis in the context of CCR6 deletion. TAM = tumor-associated macrophage.
b FACS plot showing the sorted macrophage population used for reconstitution. c Tumor-free survival curves over the course of the experiment. d Tumor
weight of control tumors generated in Ccr6WT recipients and in Ccr6−/− recipients ± TAMs. n = 6-8 tumors per group. e Macrophage numbers in
experimental groups at end-point, as assessed by flow cytometry. n = 3-4 samples per group
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of macrophages is essential at the early stages of tumor
growth.
We have thus established an essential role for CCR6 in
the tumor microenvironment, providing a causative link
between this receptor, infiltrating macrophages and mam-
mary tumor development. Hence, therapeutic opportun-
ities may be explored to control breast cancer progression,
via manipulation of the CCR6-CCL20 axis to control
tumor-promoting macrophages.
Discussion
We show here that the deletion of the chemokine recep-
tor CCR6 caused a delay in tumor onset and decreased
mammary tumor incidence in vivo in the MMTV-PyMT
transgenic mouse model. We have determined that the
underlying basis of the CCR6 oncogenic function is the
increase in numbers of infiltrating pro-tumorigenic
macrophages.
Multiple functional roles have been suggested for
members of the chemokine family and their receptors in
breast cancer pathophysiology [6], however little data
using animal models is available to support these obser-
vations. The expression of CCR6 has been reported to
correlate with higher stage and grade of human breast
cancer, and has been proposed as a prognostic tool for de-
termining relapse-free survival in breast cancer patients
[23]. However, a causative link in vivo has yet to be demon-
strated. We have employed the well-characterized MMTV-
PyMT transgenic mouse model of breast cancer, and have
found that CCR6 facilitates an earlier tumor onset and an
increased incidence of mammary tumors. Of note, CCR6
affects mammary tumorigenesis from as early as the hyper-
plastic, or hyper-proliferative, stage. This initial phase of
tumor development remains largely uncharacterized,
despite being the most treatment-effective stage of cancer
progression. Therefore, a better understanding of tumor
initiation is crucial in order to develop therapies that target
the tumorigenic process at the early stages of breast cancer.
When CCR6 was deleted in the MMTV-PyMT mouse,
tumor latency was significantly extended, and these mice
developed fewer mammary tumors than their Ccr6WT
counterparts. However, CCR6 deletion did not affect
tumorigenic properties of the epithelium as we have
found with the chemokine receptor CCR7 [29]. Stimula-
tion with CCL20 did not result in an increased prolifera-
tion rate of purified mammary epithelial cells from
hyperplastic glands or tumorous lesions in contrast to
previous studies with primary human breast peritumoral
cells [25]. Furthermore, the deletion of CCR6 did not
lead to decreased numbers of Ki67-positive proliferating
cells within intact tumor-bearing mammary glands,
pointing to an epithelial-independent function of this
receptor in breast cancer.
We have also observed that the loss of CCR6 did not
alter the numbers and functional properties of mammary
cancer stem-like cells. Transplantation experiments in
particular demonstrated that the presence of CCR6 in
donor epithelium was not required for tumor propaga-
tion in recipient mammary glands.
Further investigation demonstrated that CCR6 func-
tions via organization of the immune system during the
early stage of mammary carcinogenesis. We have shown
that the levels of TAMs are reduced by almost threefold
when CCR6 is deleted. TAMs, which have been previ-
ously identified in MMTV-PyMT tumors [48], are
widely reported to support the development of cancer
[3, 49] and in the tumor microenvironment they are
generally thought to polarize towards an alternatively-
activated M2 pro-tumor phenotype relative to the classic
M1 anti-tumor phenotype [4]. Whilst the TAMs in
MMTV-PyMT tumors are polarized towards an M2-like
subtype, we have shown that the presence of CCR6
maintains M2 TAMs as the predominant phenotype.
Therefore, it is plausible to suggest that CCR6 in breast
cancer functions to recruit pro-tumorigenic macro-
phages to the tumor immuniche [31], to support growth
of transformed epithelial cells and cancer stem cells, as
TAMs in the MMTV-PyMT model have also been
shown to also maintain stem-like cells [50].
CCR6 is not expressed on peripheral blood monocytes,
and is thought to only be acquired upon their differenti-
ation into macrophages, induced by the tumor micro-
environment [12]. In accordance with this, we found
that a high proportion of macrophages within PyMT-
driven mammary tumors express CCR6, which has not
been previously demonstrated in breast cancer. Also of
potential importance is the fact that up to 90 % of pro-
tumorigenic M2-like TAMs expressed CCR6. Our find-
ings parallel results from a recent study which showed
that CCR6-null mice bearing the adenomatosis polyposis
coli (APC)min transgene (a well-characterized model for
gastrointestinal tumorigenesis) developed fewer intes-
tinal adenomas and polyps, and that the effect of CCR6
was also linked to a significant reduction in F4/80+
macrophages [17]. Interestingly, Liu et al. also recently
demonstrated that the ligand CCL20 is secreted from
both macrophages and tumor cells in another mouse
model of colorectal cancer, potentially suggesting com-
mon regulatory mechanisms and a universal role for
CCR6 in tumors of various etiology [51].
MMTV-PyMT cancer cell transplant experiments
showed that tumor growth in a CCR6-null micro-
environment was significantly inhibited compared to
wild-type microenvironment conditions, directly dem-
onstrating that the mammary stroma is dependent
upon CCR6 for adequate tumor initiation and growth
support. The reconstitution of this CCR6-negative
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microenvironment with MMTV-PyMT Ccr6WT TAMs
restored the tumor-promoting properties of mammary
stroma, indicating that breast cancer can be therapeutic-
ally targeted through manipulation of the CCR6-CCL20
axis to control tumor-infiltrating macrophages.
CCR6 deletion has also impeded recruitment of den-
dritic cells into PyMT-driven mammary tumors. Recruit-
ment of dendritic cells into various solid tumors has
been well-documented (reviewed in [52]), and their role
in tumor progression is mainly centered around tumor
antigen presentation to lymphocyte subsets leading to
anti-tumor immune responses [53, 54]. Furthermore,
there is some evidence supporting direct tumoricidal
activity of dendritic cells [53]. As previous studies have
reported an intrinsic requirement for CCR6 in migration
and fundamental functions of dendritic cells [44, 45],
our finding of the reduced infiltration of dendritic cells
in mammary tumors may not be a facet of cancer devel-
opment in MMTV-PyMT Ccr6−/− mice, but is an inher-
ent property of dendritic cell migration at a slower rate
after CCR6 deletion.
Conclusions
In conclusion, we show here that CCR6 plays a signifi-
cant role in the initiation and at the early stage of breast
cancer development in vivo by mediating recruitment of
pro-tumorigenic macrophages to the tumor site, and
thus facilitating further progression to advanced stages
of mammary neoplasia. Results presented in this study
therefore suggest CCR6 as a potential target for thera-
peutic intervention in early breast cancer.
Methods
Mice
Mice were maintained in pathogen-free conditions in the
University of Adelaide’s Laboratory Animal Services facil-
ity. Ccr6−/− mice have been described previously [44].
Ccr6−/− females were crossed with C57BL/6 MMTV-
PyMT males and the heterozygous offspring were
interbred to produce MMTV-PyMT Ccr6WT (wild-type
for CCR6) and bigenic MMTV-PyMT Ccr6−/− mice on
the C57Bl/6 background. The University of Adelaide
institutional animal ethics committee approved all animal
experimental protocols.
Histology
Mouse mammary tissues were extracted, fixed in forma-
lin and embedded in paraffin before sectioning at 5 μm.
Haemotoxylin and eosin staining was carried out accord-
ing to standard protocols. For immunohistochemical
analysis of Ki67, slides were immersed in 0.5 % hydrogen
peroxide in methanol for 10 minutes to inhibit endogen-
ous peroxidase activity, followed by antigen retrieval by
boiling slides in 0.1 M sodium citrate buffer under
pressure. Slides were blocked for 20 minutes in 5 % nor-
mal rabbit serum in TBS/0.1 % Tween to prevent non-
specific antibody binding, and then incubated overnight
at 4 °C with mouse anti-Ki67 antibody (Vector Labs)
according to the manufacturer’s instructions. Specific
antibody binding was detected using the EnVision Dual
Link System (Vector Labs), followed by incubation with
diaminobenzidine (DAB) substrate (Dako). Sections
were counterstained with haemotoxylin, dehydrated
and mounted.
Enzyme-linked immunosorbent assay
Wells were coated with anti-CCL20 capture antibody
(R&D Systems) at 2 μg/ml overnight followed by a block-
ing step in PBS/3%BSA. Homogenized mammary tissue
lysates (in PBS containing 10 % glycerol and 1x protease
inhibitor) were added for 1.5 hours at 37 °C. Biotinylated
anti-CCL20 detection antibody (R&D Systems) was added
at 50 ng/ml for 1 hour at 37 °C followed by incubation
with streptavidin-HRP (Rockland) for 30 minutes at room
temperature. Wells were washed with PBS/0.05 % Tween
after each incubation.
Whole mount staining
Mammary glands were mounted on slides, fixed in Car-
noy’s (30 % glacial acetic acid, 30 % absolute ethanol, 10 %
chloroform), stained overnight in Carmine Alum (Stem
Cell Technologies), then dehydrated and mounted using
Permount (ThermoFisher Scientific). Image “stitching”
and analysis were performed using Image J software.
Processing mouse mammary tissue to single cell
suspension
Mouse mammary gland/tumor tissue was minced and
then digested in Dulbecco’s Modified Eagle Medium
(DMEM, Gibco) containing 1 mg/mL collagenase III,
100U/mL hyaluronidase (both from Worthington), 2 %
fetal calf serum (FCS) and penicillin-streptomycin for 3–4
hours with gentle tilting. Organoids were further digested
for 15 minutes with 6U/mL dispase (Gibco) in PBS and
20U/mL DNase I (Merck), and red blood cells were lysed
by isotonic lysis buffer (150 mM NH4Cl in 17 mM
Tris–HCl, pH 7.2). Single cells were obtained by filtration
through a 70 μm nylon mesh.
Proliferation assay
Isolated mouse mammary cells were plated in adherent
culture (1:1 mixture of DMEM and Ham’s F12 medium
(Gibco) with 10 % FCS, supplemented with 20 ng/ml
EGF, 5 μg/ml insulin, 0.5 μg/ml hydrocortisone,
penicillin-streptomycin, and 0.25 μg/ml fungazone) in a
96-well plate. The following day the medium was
replaced by DMEM with no additives, and after 2 hours
of starvation cells were stimulated with FCS (0.5 %) ±
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CCL20 (a gift from the late Professor Ian Clark-Lewis) at
a concentration of 100 ng/ml. Stimulation with EGF at
20 ng/ml was used as a positive control. The cell prolif-
eration assay was carried out 24 hours later using the
XTT Cell Proliferation Kit (ATCC) according to manu-
facturer’s instructions.
Flow cytometry
Single cell suspensions from processed mammary glands
were incubated for 30 minutes on ice in PBS/0.5%BSA
with anti-mouse primary antibodies to cell surface
markers as indicated. Antibodies used were as follows: PE-
conjugated anti-CCR6 (R&D), AlexaFluor647-conjugated
anti-CCR6, PerCP/Cy5.5-conjugated anti-CD11c, PerCP/
Cy5.5-conjugated anti-CD206, FITC-conjugated anti-CD29
(all from BioLegend), BV421-conjugated anti-B220, PE/
Cy7-conjugated anti-CD11b, PE-conjugated anti-CD24,
FITC-conjugated anti-CD4, APC-conjugated anti-CD45,
biotinylated anti-CD45.2, FITC-conjugated anti-CD45.2,
BV510-conjugated anti-CD8a, PE-conjugated anti-IL4-R
(all from BD Biosciences), PE/Cy7-conjugated anti-CD3e,
FITC-conjugated anti-F4/80 (both from eBioscience), and
biotinylated anti-F4/80 (Life Technologies). When required,
cells were also permeabilized using the FoxP3 Staining Kit,
and incubated with PerCP/Cy5.5-conjugated anti-FoxP3
(both from eBioscience).
Samples containing biotinylated antibodies were further
stained with BV510-conjugated streptavidin (BD Biosci-
ences) in PBS/0.5 % BSA for 30 minutes. Fluorescence-
minus-one (FMO) samples or cells stained with conjugated
isotype control antibodies only were used as negative
controls. After staining cells were fixed in 1 % paraformal-
dehyde and flow cytometry carried out using FACSCanto
or LSRII equipment (BD). Data analysis was performed
using FlowJo software (Tree Star Inc.). All flow cyto-
metry data presented has been gated to exclude dead
cells and debris using FSC-A/SSC-A, and to exclude
doublets using FSC-A/FSC-H plots.
Mammosphere assay
Freshly isolated mammary cells were seeded into
ultra-low attachment plates (Corning Inc.) at a con-
centration of 4x104/ml, in a 1:1 mixture of DMEM
and Ham’s F12 medium supplemented with 1xB27
(Invitrogen), 20 ng/ml FGF, 20 ng/ml EGF, 4 μg/ml
heparin (Sigma Aldrich), penicillin-streptomycin and
0.25 μg/ml fungazone. Mammosphere cultures were
incubated at 37 °C for 7 days ± CCL20 at varying
concentrations before manual enumeration under a
light microscope.
Mammary Fat Pad transplants
Mammary gland fragments of 1 mm3 size from donor
MMTV-PyMT mice (18 weeks-old) were transplanted
into contralateral sides of anaesthetized congenic non-
PyMT recipient mice as indicated (8 weeks-old) within
the inguinal mammary glands, and were monitored for
adverse reactions to surgery. After 7 weeks, recipient glands
were extracted and whole mounted for quantification.
Macrophage reconstitution assay
Mammary tumor cell suspensions were prepared from
MMTV-PyMT Ccr6WT mice at 15 weeks-old as de-
scribed above and injected into the fourth inguinal
mammary fat pads of anaesthetized 5 week-old Ccr6WT
and Ccr6−/− recipients in 80:20 % DMEM:Matrigel (BD),
at 100,000 cells/gland.
Two days later, tumor-associated macrophages were
sorted from MMTV-PyMT Ccr6WT excised and dissoci-
ated mammary tumors based on CD45+F4/80+ expression.
50,000 TAMs per gland were injected in DMEM orthoto-
pically into the inguinal glands of Ccr6−/− tumor cell
recipients. Control groups of Ccr6−/− and Ccr6WT tumor
cell recipients were sham-injected with vehicle only.
Tumor development was monitored for 6 weeks, then
mice were sacrificed and tumors extracted for analysis.
Statistical analysis
Analyses were carried out using GraphPad Prism and data
is presented as mean ± SEM unless otherwise indicated.
Significant statistical difference was estimated using
student’s t-tests, ANOVA for multiple comparisons, or
chi-square tests for distribution analysis. Tumor-free
survival curves for spontaneous tumors were graphed
using the Kaplan-Meier method and compared by the
log-rank statistic (Mantel-Cox test). Tumor-free survival
curves for the reconstitution assay were compared using
2-way ANOVA with Tukey’s multiple comparison test.
P-values were used to denote statistical significance. Levels
of significance were *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001.
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